Rituximab and low‐dose cyclosporine combination therapy for steroid‐resistant focal segmental glomerulosclerosis

We investigated the efficacy of rituximab and low‐dose cyclosporine combination therapy for focal segmental glomerulosclerosis (FSGS) in children with steroid‐resistant nephrotic syndrome (SRNS).

[1]  R. Mori,et al.  Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial , 2014, The Lancet.

[2]  K. Nakanishi,et al.  Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy , 2014, Clinical and Experimental Nephrology.

[3]  K. Kaneko,et al.  Cyclosporine versus mycophenolate mofetil for maintenance of remission of steroid-dependent nephrotic syndrome after a single infusion of rituximab , 2013, European Journal of Pediatrics.

[4]  S. Ito,et al.  Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome , 2013, Pediatric Nephrology.

[5]  M. Rastaldi,et al.  Rituximab Targets Podocytes in Recurrent Focal Segmental Glomerulosclerosis , 2011, Science Translational Medicine.

[6]  S. Ito,et al.  Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome , 2011, Pediatric Nephrology.

[7]  M. Kemper,et al.  New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome , 2011, Pediatric Nephrology.

[8]  A. Sinha,et al.  Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[9]  J. Kari,et al.  Treatment of steroid resistant nephrotic syndrome in children. , 2010, Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia.

[10]  D. Geary,et al.  Rituximab in refractory nephrotic syndrome , 2010, Pediatric Nephrology.

[11]  S. Ito,et al.  Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine , 2010, Pediatric Nephrology.

[12]  A. Meyrier.  Treatment of focal segmental glomerulosclerosis with immunophilin modulation: when did we stop thinking about pathogenesis? , 2009, Kidney international.

[13]  S. Ito,et al.  Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children , 2009, Pediatric Nephrology.

[14]  Kwanghee Kim,et al.  The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A , 2008, Nature Medicine.

[15]  O. Gefeller,et al.  Cyclosporin A is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome—a randomized controlled multicentre trial by the Arbeitsgemeinschaft für Pädiatrische Nephrologie , 2008, Pediatric Nephrology.

[16]  J. Groothoff,et al.  Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases , 2008, Pediatric Nephrology.

[17]  K. Matsuoka,et al.  Rituximab for refractory focal segmental glomerulosclerosis , 2008, Pediatric Nephrology.

[18]  J. Deegens,et al.  Rituximab: effective treatment for severe steroid-dependent minimal change nephrotic syndrome? , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[19]  A. Sinha,et al.  Rituximab in patients with the steroid-resistant nephrotic syndrome. , 2007, The New England journal of medicine.

[20]  L. Rostaing,et al.  Rituximab : effective treatment for severe steroid-dependent minimal change nephrotic syndrome ? , 2007 .

[21]  A. Salama,et al.  Drug Insight: rituximab in renal disease and transplantation , 2006, Nature Clinical Practice Nephrology.

[22]  F. Dammacco,et al.  Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor. , 2006, Blood.

[23]  V. Savin,et al.  The Focal Segmental Glomerulosclerosis Permeability Factor: Biochemical Characteristics and Biological Effects , 2004, Experimental biology and medicine.

[24]  P. Youinou,et al.  Recent Progress in the Understanding of B‐Cell Functions in Autoimmunity , 2001, Scandinavian journal of immunology.

[25]  I Royston,et al.  IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. , 1997, Blood.

[26]  F. Trovarelli,et al.  Medical Therapy , 1970 .